Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVENHIR: Azacitidine + Venetoclax in Higher-Risk CMML
2024-514878-53-00Phase 2Authorised
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine and venetoclax in chronic myelomonocytic leukemia (CMML), sponsored by Groupe Français des Myélodysplasies. Primary endpoints: Dose-limiting toxicity in safety run-in and Overall response rate after 3 and 6 cycles (modified MDS/MPN IWG). Planned start Sep 2024; status: authorised.
02
Drugs
azacitidinevenetoclax
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2024-514878-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514878-53-00.